We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+15.75%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.54B
AUM Growth
+$40.4M
Cap. Flow
-$19.3M
Cap. Flow %
-1.25%
Top 10 Hldgs %
46.87%
Holding
259
New
90
Increased
52
Reduced
41
Closed
65

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$25.6M
2
TMP icon
Tompkins Financial
TMP
+$13.1M
3
AGEN
Agenus
AGEN
+$6.13M
4
MNKD icon
MannKind Corp
MNKD
+$5.33M
5
MDVN
MEDIVATION, INC.
MDVN
+$3.71M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$28.4M
2
ABBV icon
AbbVie
ABBV
+$14.7M
3
ZTS icon
Zoetis
ZTS
+$14.2M
4
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$11.5M
5
ARWR icon
Arrowhead Research
ARWR
+$8.75M

Sector Composition

Rank Sector Weight
1 Miscellaneous 89.38%
2 Healthcare 10.49%
3 Financials 0.07%
4 Technology 0.07%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZTS icon
226
PUT
Zoetis
ZTS
$30.4B
– –
-5,491
Closed -$17M
ORKA
227
Oruka Therapeutics
ORKA
$6.12B
– –
-654
Closed -$1.28M
CDMO
228
CALL
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
– –
-354
Closed -$320K
CDMO
229
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
– –
-42,600
Closed -$385K
CDMO
230
PUT
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
– –
-539
Closed -$486K
VIRX
231
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-859
Closed -$939K
VIRX
232
PUT
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-10
Closed -$1.04M
NURO
233
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
– –
-70
Closed -$357K
NS
234
CALL
DELISTED
NuStar Energy L.P.
NS
– –
-1,350
Closed -$6.16M
NS
235
DELISTED
NuStar Energy L.P.
NS
– –
-23,584
Closed -$1.08M
NS
236
PUT
DELISTED
NuStar Energy L.P.
NS
– –
-302
Closed -$1.38M
ONCT
237
CALL
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
– –
-1
Closed -$578K
FRTX
238
CALL
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
– –
-1
Closed -$1.03M
FRTX
239
PUT
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
– –
0
– -$325K
INFI
240
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-29,188
Closed -$559K
APEN
241
DELISTED
Apollo Endosurgery, Inc.
APEN
– –
-921
Closed -$312K
ALBO
242
CALL
DELISTED
Albireo Pharma Inc
ALBO
– –
-101
Closed -$1.27M
ALBO
243
PUT
DELISTED
Albireo Pharma Inc
ALBO
– –
-26
Closed -$322K
ZVO
244
CALL
DELISTED
Zovio Inc. Common Stock
ZVO
– –
-3,130
Closed -$3.81M
ZVO
245
PUT
DELISTED
Zovio Inc. Common Stock
ZVO
– –
-4,380
Closed -$5.33M
ATHX
246
DELISTED
Athersys, Inc. Common Stock
ATHX
– –
-12,030
Closed -$511K
ENDP
247
PUT
DELISTED
Endo International plc
ENDP
– –
-1,394
Closed -$5.13M
GNMX
248
DELISTED
Aevi Genomic Medicine Inc
GNMX
– –
-427,684
Closed -$1.63M
NAVB
249
CALL
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
– –
-113
Closed -$603K
SGYPW
250
CALL
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
– –
-331,486
Closed -$610K
7 8 9
10
11

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2013 Portfolio in Review

As of Q3 2013, Sabby Management held 259 positions worth $1.54B, up 2.7% from $1.5B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sabby Management's Q3 2013 filing shows 90 new, 52 increased, 41 reduced and 65 closed positions. Its largest new stake was Tompkins Financial: 288,454 shares worth $1.02M. The largest sale was Aegerion Pharmaceuticals, an estimated $28.4M.

By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, up from 89% a quarter earlier, followed by Healthcare and Financials.

  • Sabby Management's largest Q3 2013 buy was Tompkins Financial: 288,454 shares worth $1.02M.
  • Sabby Management added most to Vertex Pharmaceuticals in Q3 2013, an estimated $25.6M increase.
  • Sabby Management's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $28.4M.
  • Sabby Management fully exited AbbVie in Q3 2013, selling an estimated $14.7M.
  • Sabby Management's ten largest holdings make up 47% of its $1.54B portfolio in Q3 2013.
  • Sabby Management opened 90 new positions and closed 65 in Q3 2013.
  • Sabby Management's portfolio value rose 2.7% quarter-over-quarter to $1.54B.

Based on Sabby Management's 13F filing for Q3 2013, filed 14 Nov 2013.